Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-DCFPyL PET/CT for Prostate Cancer Progression
NCT03800784Phase 3Withdrawn
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Oct 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of piflufolastat f 18 in prostate cancer (PCa), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Sensitivity of 18F-DCFPyL PET/CT imaging to detect metastatic prostate cancer at 3 years. Planned start Oct 2019; status: withdrawn.
02
Drugs
piflufolastat f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03800784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03800784.